Search Results - "Tho, L.M"

1833 Prognostic factors in patients with breast cancer and brain metastases: Implications for a resource limited country by Tang, W.H, Ho, G.F, Saad, M, Taib, N.A, See, M.H, Liau, P, Wahid, M.I, Tho, L.M

Get full text

OC-0253: Mid-treatment adaptive dosimetry of swallowing organs at risk(SWOAR) in head & neck cancer patients undergoing VMAT by Duffton, A, Muirhead, R, Rizwanullah, M, Paterson, C, McJury, M, Tho, L.M

Get full text

OP0007 What if all cancer patients in Malaysia had access to the best available care: How many deaths are avoidable? by Ho, G.F, Tho, L.M, Mastura, M.Y, Taib, N.A, Yip, C.H, Aina, E.N, Lim, G.C.C, Kaur, R.P, Tharan, S, Singh, M, Dass, A.S, Tan, H.C, Hoo, L.P, Lim, T.O

“…Background Malaysia spends 4% of its gross domestic product (GDP) on health care despite its wealth (GDP per head in 2011 was PPP-US$15,589). There are no data…”
Get full text

PD-0084 EFFECTS OF MRI SCAN POSITION ON CT IMAGE REGISTRATION AND TARGET DELINEATION FOR OROPHARYNX CANCER VMAT PATIENTS by McJury, M, Hanvey, S, Patterson, C, Rizwanullah, M, Thomson, M, James, A, Tho, L.M, Grose, D, Glegg, M, Foster, J

Get full text

The role of imaging in the pre-operative staging and post-operative follow-up of rectal cancer by Low, G, Tho, L.M, Leen, E, Wiebe, E, Kakumanu, S, McDonald, A.C, Poon, F.W

“…Developments in rectal cancer imaging have revolutionised the management of this condition. It has become increasingly important for oncologists and surgeons…”
Get full text

Trastuzumab-related Palmar Plantar Erythrodysaesthesia by Tho, L.M, Bose, N, Robertson, L, Bhattacharya, S, McClue, L, Anderson, L, Fraser, E, Graham, K, Yosef, H, Lumsden, G

Get full text

Oesophageal Toxicity and Hypofractionated Concurrent Chemoradiotherapy for Non-small Cell Lung Cancer by Tho, L.M, Mahmood, R, Leitch, M, Brisbane, I, Kakumanu, S, Mohammed, N

Get full text

362P Intracranial activity of dacomitinib in treatment naïve advanced EGFR mutated non-small cell lung cancer (NSCLC): Prespecified subgroup analysis of the ATORG-003 trial by Tan, A., Kim, D-W., Baisamut (Reungwetwattana), T., Yueh Ni, L., Ho, G.F., Tho, L.M., Prasongsook, N., Lee, S., Mok, T.S.K., Tan, D.S.W., Loong, H.H.F.

Get full text

1337P Real-world utilization and outcomes of dacomitinib as first-line therapy in Asian patients with advanced EGFR mutation–positive NSCLC: An interim analysis of the ARIA study by Wu, L., Li, J., Xu, C., Biswas, B., Tang, K., Wang, H., Liu, Z., Batra, U., Ho, G.F., Low, S.H.J., Lu, Y., Zhao, M., Tho, L.M., Zhao, J., He, S., Huang, J., Tang, X., Wong, C.H., Wu, Y-L.

Get full text

566P Safety of tepotinib + osimertinib in EGFR-mutant NSCLC with MET amplification after first-line osimertinib by Liam, C.K., Kim, T.M., Yang, J-J., Huang, C., Voon, P-J., Tho, L.M., Zhou, Q., Wang, J., Hayashi, H., Tan, D.S.W., Danchaivijitr, P., Nguyen, V.N., Wong, K.H., Yang, J.C-H., Le, X., Ellers-Lenz, B., Karachaliou, N., Ghori, V., Berghoff, K., Wu, Y-L.

Get full text

1358P Safety of tepotinib + EGFR TKI (osimertinib or gefitinib) in patients with EGFRm NSCLC by Nadal, E., Kim, T.M., Guarneri, V., Voon, P.J., Lim, B.K., Wislez, M., Huang, C., Liam, C.K., Mazieres, J., Tho, L.M., Hayashi, H., Nguyen, N., Chia, P.L., de Marinis, F., Brutlach, S., Adrian, S., Ellers-Lenz, B., Berghoff, K., Karachaliou, N., Wu, Y-L.

Get full text

364P Tepotinib with an EGFR-tyrosine kinase inhibitor (TKI) in patients with EGFR-mutant MET-amplified NSCLC: A case series by Ahmad, A.R., Tho, L.M., Chik, Y.K.J., Lee, W.C.K., Yang, T-Y., Le, X., Eisert, A.K., Himpe, U., De Bondt, C., Mazieres, J., Petrini, I., Lam, W-S., Joshi, K., Berghoff, K., Vlassak, S., Karachaliou, N., Van Der Wekken, A.J., Hsia, T-C.

Get full text

LBA52 Tepotinib + osimertinib for EGFRm NSCLC with MET amplification (METamp) after progression on first-line (1L) osimertinib: Initial results from the INSIGHT 2 study by Mazieres, J., Kim, T.M., Lim, B.K., Wislez, M., Dooms, C., Finocchiaro, G., Hayashi, H., Liam, C.K., Raskin, J., Tho, L.M., de Marinis, F., Nadal, E., Smit, E., Le, X., Brutlach, S., O'Brate Grupp, A.M., Adrian, S., Ellers-Lenz, B., Karachaliou, N., Wu, Y-L.

Get full text

1366TiP Tepotinib + osimertinib for EGFR-mutant NSCLC with resistance to first-line osimertinib due to MET amplification (METamp): INSIGHT 2 by Wu, Y-L., Dooms, C., Nadal, E., Raskin, J., Demedts, I., Mazieres, J., Wislez, M., Shukor, S. Abdul, Tho, L.M., Wang, C-C., Viteri, S., Le, X., How, S.H., Tan, D., Takeda, M., Veillon, R., Karachaliou, N., Ellers-Lenz, B., Smit, E.F.F.

Get full text

Chk1 is essential for chemical carcinogen-induced mouse skin tumorigenesis by Tho, L M, Libertini, S, Rampling, R, Sansom, O, Gillespie, D A

“…Chk1 is a key regulator of DNA damage checkpoint responses and genome stability in eukaryotes. To better understand how checkpoint proficiency relates to…”
Get full text

Guillain–Barre syndrome occurring after adjuvant chemo-radiotherapy for endometrial cancer by Tho, L.M., O'Leary, C.P., Horrocks, I., Al-Ani, A., Reed, N.S.

“…The association between Guillain–Barre syndrome (GBS) and malignancy is uncommon and has not been previously reported in gynecological cancers. Our case…”
Get full text

Unusual metastases from malignant pleural mesothelioma by Tho, L.M., O'Rourke, N.P.

Get full text

Acute Supraclavicular Skin Toxicity in Patients Undergoing Radiotherapy for Breast Cancer: An Evaluation of the ‘T’-Grip Method of Patient Positioning by Tho, L.M., McIntyre, A., Ross, A., Gallagher, C., Yap, C., Ritchie, D.M., Canney, P.A.

“…Supraclavicular fossa (SCF) radiotherapy plays an important part in the adjuvant management of breast cancer but data on acute radiotherapy toxicity are…”
Get full text